"Designing Growth Strategies is in our DNA"
Pyrosequencing is a procedure of DNA sequencing that identifies light radiated within the successive expansion of nucleotides during the combination of an integral strand of DNA. Pyrosequencing is done to distinguish RAN and DNA from samples and has major use of in bacteria resistance screening, drug development, epigenetics, and many other fields. Pyrosequencing is the first substitute for the conventional Sanger method for de novo DNA sequencing.
According, to a study conducted by a University in Kassel, Germany, in 2018, development of 15 nuclear microsatellite markers in Deuterocohnia (Pitcairnioideae; Bromeliaceae) was done using the 454 pyrosequencing.
To gain extensive insights into the market, Request for Customization
The increasing prevalence of chronic diseases are leading to higher demand for personalized medicine and is one of the major factors driving the growth of the global pyrosequencing market. Faster detection techniques, leading to shorter detection time and increasing use for single nucleotides facilitating the outcome of the procedure, are some of the important factors leading to the increased demand for the pyrosequencing market. Additionally, technological advancements and increasing investment by both government and private sectors in the medical and healthcare industry are some of the major factors driving the growth of the global pyrosequencing market.
The factor that is expected to inhibit the growth of the market is the high cost of the equipment’s, short reads for phylogenetic inference and high error rate.
Key Players Covered
Some of the major companies that are present in the global pyrosequencing market are Eurofins Genomics, Genomnia srl, Illumina, Inc., Macrogen, Inc., SEQOMICS Ltd., Source BioScience, Biotage AB, EpigenDx, Macrogen, Inc. and other players.
SEGMENTATION
SEGMENTATION | DETAILS |
By Application | · Diagnostics · Drug discovery · Biomarker discovery · Personalized medicine · Agriculture and animal research · Others. |
By End User | · Research centers & academic/government institutes · Hospitals · Clinics · Pharmaceutical & biotechnology companies |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa) |
At present, high investment in drug discovery and increased demand for personalized medicine has more share in the application segment. This is expected to have significant CAGR during the forecast period.
Key Insights
Regional Analysis
Among these regions, North America accounted for the largest share of the global pyrosequencing market in 2017. Higher adoption of new and advanced analytical and diagnostic tools, combined with higher awareness among patient population towards personalized medicine, and increasing incidences of new cancer cases every year in the U.S., are some of the major factors propelling the growth of the global pyrosequencing market in North America. According to the American Cancer Society, an estimated 1.6 million new cancer cases in the U.S. was reported. Europe accounted for the second largest share of the global market in 2017. However, Europe is expected to lose share in the Asia Pacific region from 2018-2025. The use of the next generation sequencing to with pyrosequencing is of the major factor for the growth of the global pyrosequencing market in the Asia Pacific region.
Key Industry Developments
US +1 833 909 2966 ( Toll Free )